Usual ACE inhibitor therapy in CKD patients is associated with lower plasma aldosterone levels than usual angiotensin receptor blocker therapy

Kidney and Blood Pressure Research

Volumn 30, Issue 5, 2007, Pages 299-305

  Haddad, Nabil ^a   Rajan, James ^a   Nagaraja, Haikady N ^a   Agarwal, Anil K ^a   Hebert, Lee A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Renal protection

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; POTASSIUM; QUINAPRIL; RAMIPRIL; RENIN; SODIUM; TELMISARTAN; VALSARTAN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RACE DIFFERENCE; RENAL PROTECTION; SEX DIFFERENCE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN;

EID: 34748887192     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106021     Document Type: Article

References (41)

1. Struthers AD: Aldosterone blockade in cardiovascular disease. Heart 2004;90:1229-1234.
2. Thohan V, Torre-Amione G, Koerner MM: Aldosterone antagonism and congestive heart failure: a new look at an old therapy. Curr Opin Cardiol 2004;19:301-308.
3. Dluhy RG, Williams GH: Aldosterone - villain or bystander? N Engl J Med 2004;351: 8-10.
4. Kathiresan S, Larson MG, Benjamin EJ, et al: Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005;18: 657-665.
5. Francis GS, Tang WH: Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J Am Coll Cardiol 2005;45:1249-1250.
6. Wilmer WA, Rovin BH, Hebert CJ, et al: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14: 3217-3232.
7. McLaughlin N, Gehr TW, Sica DA: Aldosterone-receptor antagonism and end-stage renal disease. Curr Hypertens Rep 2004;6: 327-330.
8. Hollenberg NK: Aldosterone in the development and progression of renal injury. Kidney Int 2004;66:1-9.
9. Epstein M: Aldosterone as a determinant of progressive renal dysfunction: a paradigm shift. Nephrol Self-Assess Prog 2004;3:285-295.
10. Wehling M, Spes CH, Win N, et al: Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998;83:3517-3522.
11. Romagni P, Rossi F, Guerrini L, et al: Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003;166: 345-349.
12. Arima S, Kohagura K, Xu HL, et al: Non-genomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003;14:2255-2263.
13. Rude MK, Duhaney TA, Kuster GM, et al: Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 2005;46:555-561.
14. Oberleithner H, Ludwig T, Riethmuller C, et al: Human endothelium: target for aldosterone. Hypertension 2004;43:952-956.
15. Miyata K, Rahman M, Shokoji T, et al: Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005;16:2906-2912.
16. Gonzalez M, Lobos L, Castillo F, et al: High-salt diet inhibits expression of angiotensin type 2 receptor in resistance arteries. Hypertension 2005;45:853-859.
17. Oberleithner H: Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 2005;67:1680-1682.
18. 1, and cyclin A. J Am Soc Nephrol 2005;16:2296-2305.
19. Han SY, Kim CH, Kim HS, et al: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006;17: 1362-1372.
20. Sanz-Rosa D, Cediel E, de las Heras N, et al: Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFκB/IκB system. J Hypertens 2005;23:1167-1172.
21. Hollenberg NK, Stevanovic R, Agarwal A, et al: Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004;65:1435-1439.
22. Freel EM, Connell JM: Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004;15:1993-2001.
23. Bakris GL, Siomos M, Richardson D, et al: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000; 58:2084-2092.
24. Suh A, DeJesus E, Rosner K, et al: Racial differences in potassium disposal. Kidney Int 2004;66:1076-1081.
25. Drug Facts and Comparison, 2003.
26. Schjoedt KJ, Andersen S, Rossing P, et al: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47:1936-1939.
27. Lee VC, Rhew DC, Dylan M, et al: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004;141:693-704.
28. Barnett AH, Bain SC, Bouter P, et al: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961.
29. Hebert LA, Rovin BH, Hebert CJ: Response to Dr. Brenner's comments. J Am Soc Nephrol 2004;15:1356-1357.
30. Gambertoglio JG, Amend WJ Jr, Benet LZ: Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm 1980;8:1-52.
31. Strauss MH, Hall AS: Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;14:838-854.
32. Tsuyuki RT, McDonald MA: Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006;114: 855-860.
33. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.
34. Farquharson CA, Struthers AD: Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-775.
35. Pitt B, Stier CT Jr, Rajagopalan S: Mineralo-corticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003;4:164-168.
36. Young DB, Paulsen AW: Interrelated effects of aldosterone and plasma potassium on potassium excretion. Am J Physiol 1983;244: F28-F34.
37. Pilote L, Abrahamowicz M, Rodrigues E, et al: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004;141:102-112.
38. Graciano ML, de Cavaglieri RC, Delle H, et al: Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004;15:1805-1815.
39. Campbell RC: The renin-angiotensin system: a 21st century perspective. J Am Soc Nephrol 2004;15:1963-1964.
40. Katada J, Meguro T, Saito H, et al: Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 2005; 111:2157-2164.
41. Funder JW: Cardiac synthesis of aldosterone: going, going, gone? Endocrinology 2004;145:4793-4795.